• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Accelerate Diagnostics Inc. (Amendment)

    2/24/22 4:20:14 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AXDX alert in real time by email
    SC 13G/A 1 tm227630d1_sc13ga.htm SC 13G/A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 9* (EXIT FILING)

     

    Under the Securities Exchange Act of 1934

     

     

    Accelerate Diagnostics, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    69404D108

     

    (CUSIP Number)

     

    February 18, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      

     1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Larry N. Feinberg

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    6

     

    SHARED VOTING POWER

     

    3,257,503

    7

     

    SOLE DISPOSITIVE POWER

     

    8

     

    SHARED DISPOSITIVE POWER

     

    3,257,503

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,257,503

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ¨ 

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.97%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

           

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities Exchange Commission on November 15, 2021 (the “Quarterly Report”). 

     

     

     

     1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Partners, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    2,475,749

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    2,475,749

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,475,749

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ¨

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.77%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

           

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.

     

     

     

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Institutional Partners, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    345,848

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    345,848

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    345,848

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ¨ 

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.53%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.  

     

     

     

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Ten Fund, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    349,906

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    349,906

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    349,906

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ¨

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.53%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

      

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report

     

     

     

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Investment Management, Inc. Employees' Retirement Plan

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Connecticut

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    68,000

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    68,000

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    68,000

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ¨

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.10%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

     

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.

     

     

     

      

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    The Feinberg Family Foundation

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Connecticut

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    18,000

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    18,000

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    18,000

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ¨

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.03%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

     

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.

     

     

     

      

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Associates, LLC

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    3,171,503

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    3,171,503

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,171,503

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ¨ 

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.83%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

     

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.

     

     

     

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Investment Management, Inc.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    3,239,503

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    3,239,503

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,239,503

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ¨

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.94%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

      

    * Calculated based on a total of 65,604,683 shares of common stock outstanding as of November 11, 2021, as reported by the Issuer in its Quarterly Report.

      

     

     

    This Amendment No. 9 to Schedule 13G (this “Amendment No. 9”) is being filed with respect to the Common Stock, par value $.001 (“Common Stock”) of Accelerate Diagnostics, Inc., a Delaware corporation (the “Issuer”), to amend the Schedule 13G filed on March 18, 2013, as previously amended by Amendment No. 1, filed on February 7, 2014, by Amendment No. 2, filed on January 30, 2015, by Amendment No. 3, filed on February 6, 2017, by Amendment No. 4, filed on February 6, 2018, by Amendment No. 5, filed on February 6, 2019, by Amendment No. 6, filed on February 14, 2020, by No. 7, filed on February 16, 2021, and by No. 8, filed on February 11, 2022 (as so amended, the “Schedule 13G”), in accordance with the annual amendment requirements. This Amendment No. 9 is being filed on behalf of Oracle Partners, L.P., a Delaware limited partnership (“Oracle Partners”), Oracle Ten Fund, L.P., a Delaware limited partnership (“Oracle Ten Fund”), Oracle Institutional Partners, L.P., a Delaware limited partnership (“Institutional Partners” and, collectively with Oracle Partners and Oracle Ten Fund, the “Oracle Partnerships”), Oracle Investment Management, Inc. Employees’ Retirement Plan, an employee benefit plan organized in Connecticut (the “Retirement Plan”), Oracle Associates, LLC, a Delaware limited liability company and the general partner of the Oracle Partnerships (“Oracle Associates”), Oracle Investment Management, Inc., a Delaware corporation and the investment manager to the Oracle Partnerships and the plan administrator to the Retirement Plan (the “Investment Manager”), The Feinberg Family Foundation, a foundation organized in Connecticut (the “Foundation”), and Larry N. Feinberg, the managing member of Oracle Associates, the sole shareholder, director and president of the Investment Manager and the trustee of the Foundation (each of the foregoing, a “Reporting Person” and collectively, the “Reporting Persons”). Capitalized terms used but not defined herein have the meaning ascribed thereto in the Schedule 13G. This Amendment constitutes an exit filing of the Reporting Persons.

      

    Item 4. Ownership:

      

    Item 4 of the Schedule 13G is hereby amended and restated as follows:

     

    A.Larry N. Feinberg

     

    (a)Amount beneficially owned: 3,257,503

     

    (b)Percent of class: 4.97%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 3,257,503

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 3,257,503

     

    B.Oracle Partners

     

    (a)Amount beneficially owned: 2,475,749

     

    (b)Percent of class: 3.77%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 2,475,749

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 2,475,749

      

    C.Institutional Partners

     

    (a)Amount beneficially owned: 345,848

     

    (b)Percent of class: 0.53%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 345,848

     

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 345,848

      

    D.Oracle Ten Fund

     

    (a)Amount beneficially owned: 349,906

     

    (b)Percent of class: 0.53%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 349,906

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 349,906

      

    E.Retirement Plan

     

    (a)Amount beneficially owned: 68,000

     

    (b)Percent of class: 0.10%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 68,000

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 68,000

      

    F.Foundation

     

    (a)Amount beneficially owned: 18,000

     

    (b)Percent of class: 0.03%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 18,000

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 18,000

     

     

     

     

     

    G.Oracle Associates

     

    (a)Amount beneficially owned: 3,171,503

     

    (b)Percent of class: 4.83%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 3,171,503

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 3,171,503

     

    H.Investment Manager

     

    (a)Amount beneficially owned: 3,239,503

     

    (b)Percent of class: 4.94%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 3,239,503

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 3,239,503

     

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      

    Dated:  February 24, 2022 

      

      ORACLE PARTNERS, L.P.
      By:  ORACLE ASSOCIATES, LLC, its general partner
         
      By:  /s/ Larry N. Feinberg
        Larry N. Feinberg, Managing Member
         
         
      ORACLE TEN FUND, L.P.
      By:  ORACLE ASSOCIATES, LLC, its general partner
         
      By: /s/ Larry N. Feinberg
        Larry N. Feinberg, Managing Member
         
         
      ORACLE INSTITUTIONAL PARTNERS, L.P.
      By: ORACLE ASSOCIATES, LLC, its general partner
         
      By:   /s/ Larry N. Feinberg
        Larry N. Feinberg, Managing Member
         
         
      ORACLE INVESTMENT MANAGEMENT, INC.
      EMPLOYEES’ RETIREMENT PLAN
         
       By:   /s/ Larry N. Feinberg
        Larry N. Feinberg, Trustee

     

     

     

     

      

      THE FEINBERG FAMILY FOUNDATION
         
      By: /s/ Larry N. Feinberg
        Larry N. Feinberg, Trustee
         
         
      ORACLE INVESTMENT MANAGEMENT, INC.
         
      By: /s/ Larry N. Feinberg
        Larry N. Feinberg, President 
         
         
      ORACLE ASSOCIATES, LLC
         
      By:  /s/ Larry N. Feinberg
        Larry N. Feinberg, Manager Member 
         
         
      /s/ Larry N. Feinberg
      Larry N. Feinberg, individually 

     

     

     

     

     

     

     

    Get the next $AXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXDX

    DatePrice TargetRatingAnalyst
    3/9/2022$5.00Buy → Hold
    Craig-Hallum
    More analyst ratings

    $AXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

      TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process. Accelerate has filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without material disruption to their ordinary course o

      5/8/25 9:00:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Financials

    Live finance-specific insights

    See more
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

      TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also

      1/10/25 4:05:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Shalhoub Paul Vincent

      3 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      5/1/25 6:40:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:34:08 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:32:39 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    SEC Filings

    See more
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/28/25 4:10:50 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.

      NT 10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/16/25 5:27:55 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/12/25 4:16:21 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      12/5/24 5:13:13 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Accelerate Diagnostics Inc.

      SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

      11/14/24 3:24:23 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      8/12/24 5:01:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

      TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur

      3/14/23 8:33:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

      TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our

      3/8/23 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      12/3/24 8:48:49 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Strobeck Matthew bought 100,000 shares (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:12:05 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Francesconi Louise bought 13,333 shares, increasing direct ownership by 176% to 20,927 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:11:07 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Accelerate Diagnostics downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00

      3/9/22 8:31:56 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials